Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.74−0.15 (-0.79%)
Close on Nov 13, 2026Market cap $3.00BP/E –Yield –
Denali Therapeutics cash
Cash and short-term investments held at the end of each period.
Denali Therapeutics's cash was $710.47M at Jun 30, 2026. For fiscal 2025 it was $867.88M, up 4.1% from the year before. Over ten years it grew 39.6% a year on average. The highest annual figure on record is $1.47B in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $867.88M | +4.1% |
| FY2024 | Dec 31, 2024 | $833.91M | -19.5% |
| FY2023 | Dec 31, 2023 | $1.04B | -22.5% |
| FY2022 | Dec 31, 2022 | $1.34B | +54.3% |
| FY2021 | Dec 31, 2021 | $866.91M | -41.1% |
| FY2020 | Dec 31, 2020 | $1.47B | +252.9% |
| FY2019 | Dec 31, 2019 | $416.86M | -10.5% |
| FY2018 | Dec 31, 2018 | $465.80M | +14.5% |
| FY2017 | Dec 31, 2017 | $406.76M | +907.1% |
| FY2016 | Dec 31, 2016 | $40.39M | +31.0% |
| FY2015 | Dec 31, 2015 | $30.82M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $710.47M | -21.2% |
| Q1 FY2026 | Mar 31, 2026 | $987.68M | +20.3% |
| Q4 FY2025 | Dec 31, 2025 | $867.88M | +4.1% |
| Q3 FY2025 | Sep 30, 2025 | $848.20M | +1.2% |
| Q2 FY2025 | Jun 30, 2025 | $902.06M | +0.5% |
| Q1 FY2025 | Mar 31, 2025 | $821.03M | -12.5% |
| Q4 FY2024 | Dec 31, 2024 | $833.91M | -19.5% |
| Q3 FY2024 | Sep 30, 2024 | $838.13M | -24.5% |
| Q2 FY2024 | Jun 30, 2024 | $897.62M | -24.7% |
| Q1 FY2024 | Mar 31, 2024 | $938.44M | -27.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.04B | -22.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.11B | +0.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.19B | +11.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.29B | +34.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.34B | +54.3% |
| Q3 FY2022 | Sep 30, 2022 | $1.11B | +6.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.07B | -18.3% |
| Q1 FY2022 | Mar 31, 2022 | $959.02M | -32.2% |
| Q4 FY2021 | Dec 31, 2021 | $866.91M | -41.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.04B | +8.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.31B | +137.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.41B | +140.3% |
| Q4 FY2020 | Dec 31, 2020 | $1.47B | +252.9% |
| Q3 FY2020 | Sep 30, 2020 | $962.70M | +100.8% |
| Q2 FY2020 | Jun 30, 2020 | $551.08M | +15.1% |
| Q1 FY2020 | Mar 31, 2020 | $588.75M | +21.3% |
| Q4 FY2019 | Dec 31, 2019 | $416.86M | -10.5% |
| Q3 FY2019 | Sep 30, 2019 | $479.39M | +27.9% |
| Q2 FY2019 | Jun 30, 2019 | $478.60M | +28.5% |
| Q1 FY2019 | Mar 31, 2019 | $485.48M | +30.0% |
| Q4 FY2018 | Dec 31, 2018 | $465.80M | +14.5% |
| Q3 FY2018 | Sep 30, 2018 | $374.96M | +933.8% |
| Q2 FY2018 | Jun 30, 2018 | $372.59M | +802.0% |
| Q1 FY2018 | Mar 31, 2018 | $373.40M | +916.0% |
| Q4 FY2017 | Dec 31, 2017 | $406.76M | +907.1% |
| Q3 FY2017 | Sep 30, 2017 | $36.27M | +17.7% |
| Q2 FY2017 | Jun 30, 2017 | $41.31M | – |
| Q1 FY2017 | Mar 31, 2017 | $36.75M | – |
| Q4 FY2016 | Dec 31, 2016 | $40.39M | – |
| Q4 FY2015 | Dec 31, 2015 | $30.82M | – |
See a number that looks wrong?